Investing

Cadence Pharmaceuticals (CADX): Another Biotech Implosion

Shares in Cadence Pharmaceuticals (CADX) are off as much as 50% on news that one of its drugs had failed in trials. According to Reuters "the biopharmaceutical company said one trial did not meet its main goal of significantly reducing pain following abdominal gynecologic surgery, while the other trial met its primary target of a significant reduction of fever."

The company loses about $10 million a quarter on no revenue. At the end of the third quarter it has $56 million in cash. Not much runway

Douglas A. McIntyre

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.